The overall goal of this application is to apply genomics to risk assessment in acute myocardial infarction (MI). Acute MI is triggered by atherosclerotic plaque rupture and subsequent coronary thrombosis. Functional polymorphisms in genes encoding platelet adhesion molecules, coagulation factors, and fibrinolytic proteins have been identified. These polymorphisms have been associated with an increased risk of MI. However, the functional and clinical significance of these potentially prothrombotic polymorphisms in the setting of an acute MI remains unexplored. Our hypothesis is that in acute MI, prothrombotic polymorphisms will alter the balance between thrombosis and fibrinolysis, impair resolution of coronary thrombi, and thereby affect responses to pharmacologic reperfusion therapy and outcomes. We will test this hypothesis in CLARITY-TIMI 28, a phase Ill clinical trial evaluating clopidogrel in 2200 patients undergoing thrombolysis for acute Ml.
Our specific aims are to: (1) determine the associations between prespecified polymorphisms and thrombosis-related outcomes including platelet activation, hemostatic markers of coagulation and fibrinolysis, ST segment resolution, infarct-related artery patency, and clinical ischemic events; (2) determine whether significant gene-environment interactions exist between prothrombotic polymorphisms and clinical cardiovascular risk factors; and (3) determine whether significant pharmacogenomic interactions exist between prothrombotic polymorphisms and antithrombotic therapies. Baseline blood samples will be obtained in patients for DNA extraction. Known polymorphisms in genes involved in hemostasis will be genotyped by the Harvard-Partners Genotyping Facility. As part of the parent trial, platelet function studies, ECGs, and coronary angiography will be performed, and patients will be followed for 30 days for death and recurrent ischemic events. In addition, for this proposed ancillary study, hemostatic parameters will be measured at baseline and prior to angiography. Crude associations between genotypes and outcomes will be assessed using (2 tests and ANOVA. Relevant baseline clinical characteristics will be adjusted for in multivariable regression analyses using an additive genetic model. Genomic control will be employed to detect and control for population stratification. Interaction terms will be incorporated into regression models to explore gene-environment and pharmacogenomic interactions.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL072879-02
Application #
6661969
Study Section
Special Emphasis Panel (ZHL1-CSR-H (S2))
Program Officer
Desvigne-Nickens, Patrice
Project Start
2002-09-30
Project End
2006-07-31
Budget Start
2003-08-01
Budget End
2004-07-31
Support Year
2
Fiscal Year
2003
Total Cost
$389,250
Indirect Cost
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Sabatine, Marc S; Ploughman, Lynn; Simonsen, Katy L et al. (2008) Association between ADAMTS1 matrix metalloproteinase gene variation, coronary heart disease, and benefit of statin therapy. Arterioscler Thromb Vasc Biol 28:562-7
Sabatine, Marc S; Morrow, David A; McCabe, Carolyn H et al. (2006) Combination of quantitative ST deviation and troponin elevation provides independent prognostic and therapeutic information in unstable angina and non-ST-elevation myocardial infarction. Am Heart J 151:25-31
Sabatine, Marc S; Cannon, Christopher P; Gibson, C Michael et al. (2005) Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352:1179-89
Sabatine, Marc S; Morrow, David A; Giugliano, Robert P et al. (2005) Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation 111:2042-9
Sabatine, Marc S; Cannon, Christopher P; Gibson, C Michael et al. (2005) Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 294:1224-32
Chen, A A; Sabatine, M S (2003) The management of unstable angina and non-ST-segment elevation myocardial infartion. Minerva Cardioangiol 51:433-45